Loss of EphA7 Expression in Basal Cell Carcinoma by Hypermethylation of CpG Islands in the Promoter Region

Jie Liu, Na Yu, Xiao Feng, Yan He, Kang Lv, Haiping Zhu, and Jiandong Wang

1Department of Dermatology, Taixing People’s Hospital, Jiangsu Taixing 225400, China
2Department of Radiotherapy, Taixing People’s Hospital, Jiangsu Taixing 225400, China
3Department of Pathology, Jinling Hospital, Nanjing University School of Medicine, Nanjing 210002, China

Correspondence should be addressed to Haiping Zhu; 13775783510@163.com and Jiandong Wang; jd_wang@outlook.com

Received 28 April 2021; Revised 22 December 2021; Accepted 3 January 2022; Published 22 January 2022

Copyright © 2022 Jie Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Basal cell carcinoma (BCC) is the most common malignancy worldwide, with increasing incidence. BCCs present low mortality but high morbidity, and its pathogenesis remains unclear. Eph receptors have been implicated in tumorigenesis. EphA7 plays a role as a tumor suppressor in certain cancers. We checked EphA7 expression levels and methylation status in a set of BCCs, benign skin diseases, and compound nevus tissue samples using immunohistochemistry. EphA7 protein was positively expressed in normal basal cells, benign skin diseases, and compound nevus cells, but lost in areas of BCC tissues. We detected hypermethylation in BCC tissue samples with reduced expression of EphA7. There is a significant relationship between the expression level of EphA7 receptor protein and the methylation status of CpG islands in the EphA7 promoter region ($P < 0.001$). To our knowledge, this is the first study to report the EphA7 expression profile and hypermethylation of EphA7 in BCC. The role of the EphA7 gene and the status of hypermethylation in tumorigenesis and treatment of BCC warrant further investigation.

1. Introduction

According to the American Cancer Society, skin cancer is the most common cancer, accounting for about half of all cancers in the United States [1]. Basal cell carcinoma (BCC) is the most common malignant neoplasm in humans and constitutes approximately 80% of all nonmelanoma skin cancers, with increasing incidence [2]. BCC usually arises from the basal cells of the epidermis of follicular structures, although a small percentage may originate from the outer root sheath of the pilosebaceous unit. BCC is the most common cancer of the skin and has a good prognosis. Despite the low mortality rates and the rare occurrence of metastasis, basal cell carcinoma may be locally invasive and relapse after treatment, causing significant morbidity. This could be due to the existence of cancers stem cells in surgical margins of BCCs, as suggested by Milosevic et al. [3]. Local tissue destruction and disfigurement can be considerable if not limited by early detection and treatment. The etiology of BCC is multifactorial, involving a combination of genotype, phenotype, and environmental factors [2]. UV radiation exposure is the most important environmental risk factor, while other risk factors include childhood sunburns, family history of skin cancer, tanning bed use, chronic immunosuppression, photosensitizing drugs, ionizing radiation, and exposure to carcinogenic chemicals [4]. Although the pathogenesis of BCC is still unclear, many genes are thought to be involved. The patched/hedgehog intracellular signaling pathway is responsible for regulating cell growth and is associated with BCC development [5]. Inactivation of PTCH1 or activating SMOm mutations leads to aberrant hedgehog pathway activation and BCC formation. P53 mutations affecting UV detection are also common in BCCs [6–10].

Erythropoietin-producing human hepatocellular receptor (Eph) is a superfamily of tyrosine kinase receptors, which plays a role in embryonic development and cancers [11–15]. There are two subfamilies of Eph receptors (EphA and B) and two ligands for Eph receptors (EphrinA and B). The
Eph/Ephrin proteins are differentially expressed in various adult human tissues and cancers [13, 16-19]. Eph/Ephrin signaling affects cell morphology, migration, and adhesion, all of which play a pivotal role in tissue maintenance [12, 15, 20]. Emerging evidence points to a dual role for Eph receptors in both tumor promotion and suppression [21]. For example, EphA2 is highly expressed in certain human cancers and plays a role as an oncogene [22-27], while EphA7, an Eph receptor, plays roles in the development of the central and peripheral nervous system, limb patterning, and innervation [28-30]. Expression of EphA7 has been detected in some types of human cancer [31-36], EphA7 is downregulated in colorectal cancer, prostate cancer, and gastric cancer by hypermethylation of its promoter. However, the expression of EphA7 in BCC remains unclear. In this study, we examined the EphA7 expression in a set of BCCs, benign skin diseases, and compound nevus tissue samples. We also investigated the methylation status in CpG islands of the EphA7 promoter region in BCC samples.

2. Materials and Methods

2.1. Patients and Samples. A cohort of 67 Chinese individuals, including 45 patients with BCC (including 12 superficial, 30 nodular, and 3 infiltrating subtype), 10 patients with benign skin diseases (6 pilocytoma, 3 erythema papules, and 1 pustule), and 12 patients with compound nevus, were retrieved from the Pathology Department archives of Taixing People’s Hospital. The ages of the 67 patients ranged between 43 and 96 years, while the patients’ mean age was 69.3 years. The protocol used in this study was approved by the Ethics Committee of the Taixing People’s Hospital in accordance with the standards of the 1964 Declaration of Helsinki.

2.2. Immunohistochemistry. Immunohistochemical staining was performed using Envision Plus system and DAB kit. Briefly, the 4μm tissue sections were deparaffinized using xylene, dehydrated in an ethanol gradient, and then rehydrated with deionized water. The sections were autoclaved in 1 mM EDTA buffer (pH 8.0) at 120°C for 2 min and cooled to 30°C. The nonspecific sites in the slides were blocked using 10% normal calf serum in phosphate-buffered saline (PBS) for 10 min. Next, an anti-EphA7 polyclonal antibody (Abgent, San Diego, CA, USA) at a 1:600 dilution in antibody diluent solution (Zymed, Invitrogen, Carlsbad, CA, USA) was dropped onto the slides and incubated at 4°C overnight. Following incubation, the slides were washed with PBS, stained with 3′,3′-diaminobenzidine, and counterstained with hematoxylin.

EphA7 expression was assessed as positive when the cytoplasm was stained brown. The immunoreactivity of EphA7 was evaluated independently by two pathologists. Any differences in results were verified by consensus.

2.3. DNA Extraction and Bisulfite Treatment. DNA was extracted from formalin-fixed, paraffin-embedded tissues using the QIAmp DNA FFPE tissue kit (Qiagen, Germany) according to the manufacturer’s protocol. Briefly, 10 slides with a thickness of 10μm from tissues were deparaffinized using xylene and dehydrated by gradient ethanol. The concentration and quality of DNA in the elution buffer were determined by measuring the absorbance at 260/280 nm in a spectrophotometer.

Genomic DNA was subjected to bisulfite conversion using the EZ DNA methylation Gold Kit (ZYMO Research, 17062 Murphy Ave, Irvine, CA92614, USA). Briefly, 1μg genomic DNA in 20μl was added to 130μl CT conversion reagent in a PCR tube. Next, the sample tube was placed in a thermal cycler before performing the following steps: 98°C for 10 min, 64°C for 2.5 h, and 4°C for cool. We next added 600μl of M-biding buffer to a Zymo-Spin IC column and placed the column into a collection tube. The sample was then loaded into the column and mixed by inverting. The sample was centrifuged at full speed for 30s and the flow-through was discarded. Next, we added 100μl of M-Wash buffer to the column and centrifuged at full speed for 30s. Next, we added 200μl of M-Desulphonation buffer to the column and let stand at room temperature for 15 min before centrifuging at full speed for 30s. After rinsing with M-Wash buffer twice, we placed the column into a 1.5 ml microcentrifuge tube, added 30μl of M-Elution buffer to the column matrix, and centrifuged for 30s at full speed to elute the DNA. The DNA was stored at −20°C for later use.

2.4. Methylation Detection. The methylation status of CpG islands in the EphA7 promoter region was detected by a direct sequencing method. First, 1μl bisulfite-treated genomic DNA was amplified in a 30μl reaction mixture containing 1× buffer, 1U Takara ExTaq Hotstart Taq (Takara, Dalian, China), 260μmol/L dNTPs, and 0.3μmol/L of the bisulfite PCR (BSP) primer sets. The BSP primers were as follows: 5′-TTAGGTTGGTTGGAATTG-3′ (forward) and 5′-CAATAACACTTCTATAACC-3′ (reverse); the products were 155bp long. The PCR involved 2 min at 95°C, 40 cycles of 94°C for 30s, 58°C for 30s, 72 cycles for 1 min, and finally 10 min at 72°C. The PCR products were subjected to direct sequencing by Sangon Biotech Company (Sangon Biotech, Shanghai, China).

2.5. Statistical Analysis. The statistical significance of intergroup differences was analyzed by chi-squared test. All statistical analyses were performed using SPSS software. For all statistical tests, a two-sided P value of <0.05 was considered statistically significant.

3. Results

3.1. Loss of EphA7 Expression in BCC. The expression level of EphA7 receptor in BCC, benign skin diseases, and compound nevus was checked using a specific anti-EphA7 polyclonal antibody for immunohistochemistry. As shown in Figure 1, EphA7 protein was mainly present in the cytoplasm, as indicated by brown staining, while EphA7 protein was positively detected in normal basal cells (Figure 1(a)).
The EphA7 expression level in BCC varied among patients’ samples. Positive expression of EphA7 receptor was detected in 25 of 45 cases (55.6%) (Figure 1(b)), while negative expression was noted in 20 of 45 cases (44.4%) (Figure 1(c)). Downregulation of EphA7 was detected in 20 of 45 (44.4%) BCC samples (Figure 1(d)). No significant difference in EphA7 expression was found among different subtypes ($P = 0.722$, Table 1). Positive expression of EphA7 receptor was detected in benign skin diseases (pilocytoma) (Figure 2(a)) and compound nevus (Figure 2(b)).

Hypermethylated CpG islands were detected in 18 of 20 (90%) BCC samples with negative expression of EphA7 and in 1 of 25 (4%) BCC samples with positive expression of EphA7 (Table 2 and Figure 4). There was a significant relationship between the expression level of EphA7 receptor protein and the methylation status of CpG islands in the EphA7 promoter region ($P < 0.001$).

### Table 1: EphA7 expression in different subtypes of BCC.

| Subtype of BCC  | EphA7 (+) | EphA7 (–) | $P$ value |
|-----------------|-----------|-----------|-----------|
| Superficial type| 7         | 5         | 0.722     |
| Nodular type    | 17        | 13        |           |
| Infiltrating type| 1        | 2         |           |

The EphA7 expression level in BCC varied among patients’ samples. Positive expression of EphA7 receptor was detected in 25 of 45 cases (55.6%) (Figure 1(b)), while negative expression was noted in 20 of 45 cases (44.4%) (Figure 1(c)). Downregulation of EphA7 was detected in 20 of 45 (44.4%) BCC samples (Figure 1(d)). No significant difference in EphA7 expression was found among different subtypes ($P = 0.722$, Table 1). Positive expression of EphA7 receptor was detected in benign skin diseases (pilocytoma) (Figure 2(a)) and compound nevus (Figure 2(b)).

### 3.2. Hypermethylation of CpG Islands in EphA7 in BCC.

Two CpG islands were found upstream of the translation start site ATG in the EphA7 promoter-associated region (Figure 3(a)). The CpG island prediction option is as follows: Obs/Exp (observed/expected CpG ratio)= 0.6, and GC percentage (GC%)= 50. Bisulfite sequencing PCR (BSP) primer sets were selected to amplify bisulfite-treated DNA. There were 11 CG sites in PCR products with 155bp long (Figure 3(b)). All of the 45 BCC tissue samples were subjected to BSP assay.

Hypermethylated CpG islands were detected in 18 of 20 (90%) BCC samples with negative expression of EphA7 and in 1 of 25 (4%) BCC samples with positive expression of EphA7 (Table 2 and Figure 4). There was a significant relationship between the expression level of EphA7 receptor protein and the methylation status of CpG islands in the EphA7 promoter region ($P < 0.001$).

### 4. Discussion

The expression of Eph receptors and Ephrin ligands is often ambiguous in various human cancers. Interestingly, Eph receptors show both tumor promoter and suppressor roles in human cancers. Indeed, EphA7 has been shown to play both tumor-suppressive and oncogenic roles in colorectal cancer, prostate cancer, and lung cancer [31, 37–42]. Upregulation of EphA7 in gallbladder adenocarcinoma and glioblastoma has also been shown to be related to metastasis and poor survival [33, 36]. Moreover, knockdown of EphA7 in lung adenocarcinoma has been found to increase apoptosis through regulation of BAX, Bcl-2, and caspase-3 [43]. These studies showed that EphA7 plays a role as an oncogene through stimulation of migration or invasion and inhibition of apoptosis. However, reduced expression of EphA7 due to hypermethylation of CpG island was found in prostate cancer, gastric cancer, and colorectal cancer [32, 34, 35]. In previous works, we found that downregulation of EphA7 in colorectal cancer and gastric cancer by hypermethylation [34, 35]. Other
molecular mechanisms responsible for the loss of EphA7 expression include the long noncoding RNA SNHG14 targeting EZH2 and miR-488 [44, 45].

Recently, the drugs JI-101, XL647, and KB004 have been developed to target various Eph receptors [46–48]. Eph receptors and Ephrin ligands construct a group of complex signaling pathways. It is suitable for the selection of clinical therapy targeting. Akt protein is one of the most common targets downstream of all Eph receptors, and mediates pro- or antitumorigenic effects by regulating proliferation and migration, as seen with the EphA7 receptor [49]. Drugs targeting Eph receptors have made considerable progress owing to the increased insight into the interactions, mechanisms, and expression patterns of Eph receptors. This research direction will create a better understanding of the impact of drugs that intervene with Eph/Ephrin signaling. We believe that more drugs targeting Eph receptors will be evaluated in clinical trials, following which, it is likely that EphA7 receptor will gain a place in the therapy for BCC treatment.

Our data show that EphA7 is differentially expressed in BCC tissues. Downregulation of EphA7 was detected in 44.4% (20/45) of samples, while EphA7 expression was absent in 5 superficial, 13 nodular, and 2 infiltrating subtypes. There was no significant difference in EphA7 expression among different subtypes. Hypermethylated CpG islands were detected in 18 of 20 (90%) BCC samples with negative expression of EphA7 and in 1 of 25 (4%) BCC samples with positive expression of EphA7. Two BCC samples had loss of EphA7 expression, with no DNA hypermethylation detected. We deduced that this may be due to other mechanisms such as mutations, microRNA, and long noncoding RNA regulation. However, 4% of BCC samples with positive expression of EphA7 were detected hypermethylation, suggesting heterogeneous expression of EphA7 in BCC samples.

**Table 2:** EphA7 expression in BCC and association with hypermethylation of CpG island.

|           | EphA7 (+) | EphA7 (−) | P value |
|-----------|-----------|-----------|---------|
| Methylated CpG island | 1         | 18        | <0.001  |
| Unmethylated CpG island | 24        | 2         |         |

![Figure 2](image1.png) **Figure 2:** EphA7 receptor was detected in benign skin disease (pilocytoma) (a) and compound nevus (b); magnification, 200x.

![Figure 3](image2.png) **Figure 3:** (a). Two CpG islands were identified in the EphA7 promoter region. (b) Bisulfite sequencing primer (BSP) sets, locations, and detailed DNA sequence of amplified fragments.
This is a preliminary study for EphA7 receptor expression in BCC. Our results revealed the association of EphA7 downregulation with hypermethylation of CpG islands in the promoter in BCC. However, there are several limitations to this study, including the small sample size, the tissue samples being only from the Asian population with low occurrence rate of BCC, and no functional tests being performed on the EphA7 gene in BCC cell lines, including 5’AzaDC treatment for reverse EphA7 expression of EphA7 in BCC cell lines.

In summary, EphA7 protein was differently expressed in BCC samples but positively expressed in normal basal cells, benign skin diseases, and compound nevus. Reduced expression of EphA7 in BCC is mainly due to hypermethylation of CpG islands. To our knowledge, this is the first time that the EphA7 expression profile and hypermethylation has been reported in BCC. The role of the EphA7 gene and the status of hypermethylation in tumorigenesis and treatment of BCC are worthy of further research.

Data Availability
The data that support the findings of this study are available from the corresponding author, WJD, upon reasonable request.

Conflicts of Interest
The authors declare that no conflict of interest exists.

Authors’ Contributions
JL, XF, YH, and NY were involved in IHC and methylation detection, KL in data analysis, and JDW in review and writing. Jie Liu and Na Yu have equally contributed to this work.

References
[1] A. I. Rubin, E. H. Chen, and D. Ratner, “Basal-cell carcinoma,” The New England Journal of Medicine, vol. 353, no. 21, pp. 2262–2269, 2005.
[2] E. Kasumagic-Haililovic, M. Hasic, and N. Orcina-Kurtovic, “A clinical study of basal cell carcinoma,” Medical Archives, vol. 73, no. 6, pp. 394–398, 2019.
[3] M. Milosevic, M. Lazarevic, B. Tolić et al., “Characterization of stem-like cancer cells in basal cell carcinoma and its surgical margins,” Experimental Dermatology, vol. 27, no. 10, pp. 1160–1165, 2018.
[4] D. P. Kim, K. J. B. Kus, and E. Ruiz, “Basal cell carcinoma review,” Hematology/Oncology Clinics of North America, vol. 33, no. 1, pp. 13–24, 2019.
[5] V. N. Sehgal, K. Chatterjee, D. Pandhi, and A. Khurana, “Basal cell carcinoma: pathophysiology,” Skinmed, vol. 12, no. 3, pp. 176–181, 2014.
[6] S. T. Oh, A. Stark, and J. Reichrath, “The p 53 signalling pathway in cutaneous basal cell carcinoma: an immunohistochemical description,” Acta Dermato-Venereologica, vol. 100, no. 6, pp. adv00098–adv00092, 2020.
[7] H. Backvall, S. Stromberg, A. Gustafsson et al., “Mutation spectra of epidermal p 53 clones adjacent to basal cell carcinoma and squamous cell carcinoma,” Experimental Dermatology, vol. 13, no. 10, pp. 643–650, 2004.
[8] M. Wehrhau, M. Bader, G. Lehnert, C. Wittekind, A. Tannapfel, and R. Wibizkyz, “Carcinogen-specific mutation pattern in the p53 tumour suppressor gene in UV radiation-induced basal cell carcinoma,” International Archives of Occupational and Environmental Health, vol. 75, no. 4, pp. 272–276, 2002.
[9] H. Zhang, X. L. Ping, P. K. Lee et al., “Role of _PTCH_ and _p53_ genes in early-onset basal cell carcinoma,” The American Journal of Pathology, vol. 158, no. 2, pp. 381–385, 2001.
[10] A. Ouhit, H. Nakazawa, H. Yamashita et al., “UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma,” Journal of the National Cancer Institute, vol. 90, no. 7, pp. 523–531, 1998.
[11] E. Nievergall, M. Lackmann, and P. W. Janes, “Eph-dependent cell-cell adhesion and segregation in development and cancer,” Cellular and Molecular Life Sciences, vol. 69, no. 11, pp. 1813–1842, 2012.
[12] A. Merlos-Suarez and E. Batlle, “Eph-ephrin signalling in adult tissues and cancer,” Current Opinion in Cell Biology, vol. 20, no. 2, pp. 194–200, 2008.
[13] C. Hafner, B. Becker, M. Landthaler, and T. Vogt, “Expression profile of Eph receptors and ephrin ligands in human skin and downregulation of EphA1 in nonmelanoma skin cancer,” Modern Pathology, vol. 19, no. 10, pp. 1369–1377, 2006.
[14] H. Surawski, P. C. Ma, and R. Salgia, “The role of ephrins and Eph receptors in cancer,” Cytokine & Growth Factor Reviews, vol. 15, no. 6, pp. 419–433, 2004.
[15] A. C. Andres and A. Ziemiecki, “Eph and ephrin signaling in mammary gland morphogenesis and cancer,” Journal of Mammary Gland Biology and Neoplasia, vol. 8, no. 4, pp. 475–485, 2003.
[16] N. N. Phan, S. Liu, C. Y. Wang et al., “Overexpressed gene signature of EPH receptor A/B family in cancer patients.
comprehensive analyses from the public high-throughput database," International Journal of Clinical and Experimental Pathology, vol. 13, no. 5, pp. 1220–1242, 2020.

[17] P. W. Janes, M. E. Vail, H. K. Gan, and A. M. Scott, "Antibody targeting of Eph receptors in cancer," Pharmaceuticals (Basel), vol. 13, no. 5, p. 88, 2020.

[18] I. Nikas, H. S. Ryu, and S. Theocharis, "Viewing the Eph receptors with a focus on breast cancer heterogeneity," Cancer Letters, vol. 434, pp. 160–171, 2018.

[19] S. Mateo-Lozano, S. Bazzocco, P. Rodrigues et al., "Loss of the Eph receptor B6 contributes to colorectal cancer metastasis," Scientific Reports, vol. 7, no. 1, p. 43702, 2017.

[20] J. Winter, S. Roepecke, S. Krause et al., "Comparative 3'UTR analysis allows identification of regulatory clusters that drive Eph/ephrin expression in cancer cell lines," PLoS One, vol. 3, no. 7, article e2780, 2008.

[21] O. J. Buckens, B. El Hassouni, E. Giovannetti, and G. J. Peters, "Roles in limb patterning and innervation, of the receptor EphA7 from its tyrosine kinase-negative isoform on neurons in adult mouse brain," Prostate, vol. 41, no. 4, pp. 275–280, 1999.

[22] F. Hou, W. Yuan, J. Huang et al., "Overexpression of EphA2 correlates with epithelial-mesenchymal transition-related proteins in gastric cancer and their prognostic importance for postoperative patients," Medical Oncology, vol. 29, no. 4, pp. 2691–2700, 2012.

[23] A. A. Kamat, D. Coffey, W. M. Merritt et al., "EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer," Cancer, vol. 115, no. 12, pp. 2684–2692, 2009.

[24] Y. G. Lin, L. Y. Han, A. A. Kamat et al., "EphA2 overexpression is associated with angiogenesis in ovarian cancer," Cancer, vol. 109, no. 2, pp. 332–340, 2007.

[25] T. Saito, N. Masuda, T. Miyazaki et al., "Expression of EphA2 and E-cadherin in colorectal cancer: correlation with cancer metastasis," Oncology Reports, vol. 11, no. 3, pp. 605–611, 2004.

[26] M. S. Kinch and K. Carles-Kinch, "Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer," Clinical & Experimental Metastasis, vol. 20, no. 1, pp. 59–68, 2003.

[27] J. Walker-Daniels, K. Coffman, M. Azimi et al., "Overexpression of the EphA2 tyrosine kinase in prostate cancer," The Prostate, vol. 41, no. 4, pp. 275–280, 1999.

[28] T. Ciossek, A. Ullrich, E. West, and J. H. Rogers, "Segmentation of the central and peripheral nervous system," Mechanisms of Development, vol. 68, no. 1-2, pp. 173–177, 1997.

[29] M. Gajdzis, S. Theocharis, P. Gajdzis et al., "Ephrin receptors (Eph): EphA1, EphA5, and EphA7 expression in uveal melanoma-associations with clinical parameters and patient survival," Life, vol. 10, no. 10, p. 225, 2020.

[30] M. Guan, C. Xu, F. Zhang, and C. Ye, "Aberant methylation of EphA7 in human prostate cancer and its relation to clinicopathologic features," International Journal of Cancer, vol. 124, no. 1, pp. 88–94, 2009.

[31] D. C. Liu and Z. L. Yang, "MTDH and EphA7 are markers for metastasis and poor prognosis of gallbladder adenocarcinoma," Diagnostic Cytopathology, vol. 41, no. 3, pp. 199–205, 2013.

[32] J. Wang, H. Kataoka, M. Suzuki et al., "Downregulation of EphA7 by hypermethylation in colorectal cancer," Oncogene, vol. 24, no. 36, pp. 5637–5647, 2005.

[33] J. Wang, G. Li, H. Ma et al., "Differential expression of EphA7 receptor tyrosine kinase in gastric carcinoma," Human Pathology, vol. 38, no. 11, pp. 1649–1656, 2007.

[34] L. F. Wang, E. Fokas, J. Juricko et al., "Increased expression of EphA7 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients," BMC Cancer, vol. 8, no. 1, p. 79, 2008.

[35] O. G. Shaker, G. Ayele, and A. M. Abdelhamid, "Circulating microRNA-944 and its target gene EphA7 as a potential biomarker for colorectal cancer," Archives of Physiology and Biochemistry, vol. 17, pp. 1–7, 2020.

[36] K. Kano, K. Horiiuchi, Y. Yoshida et al., "EphA7 perivascular cells as myogenic and angiogenic precursors improving skeletal muscle regeneration in a muscular dystrophic mouse model," Stem Cell Research, vol. 47, article 101914, 2020.

[37] M. Ucuncu, M. Serilmaz, M. Sari, S. Bademler, and S. Karabulut, "The diagnostic significance of PDGF, EphA7, CCR5, and CCL5 levels in colorectal cancer," Biomolecules, vol. 9, no. 9, p. 464, 2019.

[38] T. M. Nguyen, A. Arthur, A. C. Zannettino, and S. Grontos, "EphA5 and EphA7 forward signaling enhances human hematopoietic stem and progenitor cell maintenance, migration, and adhesion via Rac1 activation," Experimental Hematology, vol. 48, pp. 72–78, 2017.

[39] S. Li, Z. Wu, P. Ma et al., "Ligand-dependent EphA7 signaling inhibits prostate tumor growth and progression," Cell Death & Disease, vol. 8, no. 10, article e3122, 2017.

[40] M. Liu, K. Zhou, and Y. Cao, "MicroRNA-944 affects cell growth by targeting EPHA7 in non-small cell lung cancer," International Journal of Molecular Sciences, vol. 17, no. 10, p. 1493, 2016.

[41] R. Li, Y. Sun, A. Jiang et al., "Knockdown of ephrin receptor A7 suppresses the proliferation and metastasis of A549 human lung cancer cells," Molecular Medicine Reports, vol. 13, no. 4, pp. 3190–3196, 2016.

[42] W. di, X. Weinan, L. Xin et al., "Long noncoding RNA SNHG14 facilitates colorectal cancer metastasis through targeting EZH2-regulated EPHA7," Cell Death & Disease, vol. 10, no. 7, p. 514, 2019.

[43] X. Wu, L. Yan, Y. Liu, W. Xian, L. Wang, and X. Ding, "MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7," PLoS One, vol. 12, no. 6, article e0175553, 2017.

[44] M. Das, S. K. Padha, A. Frymoyer et al., "A safety, tolerability, and pharmacokinetic analysis of two phase I studies of multitargeted small molecule tyrosine kinase inhibitor XL647 with an intermittent and continuous dosing schedule in patients with advanced solid malignancies," Cancer Chemotherapy and Pharmacology, vol. 82, no. 3, pp. 541–550, 2018.

[45] R. T. Swords, P. L. Greenberg, A. H. Wei et al., "Corrigendum to ‘KR004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced
hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729], “Leukemia research, vol. 59, p. 65, 2017.

[48] T. L. Werner, M. L. Wade, N. Agarwal et al., “A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-β, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort,” Investigational New Drugs, vol. 33, no. 6, pp. 1217–1224, 2015.

[49] H. Y. Liu, J. Chang, G. D. Li, Z. H. Zhang, J. Tian, and Y. S. Mu, “MicroRNA-448/EPHA7 axis regulates cell proliferation, invasion and migration via regulation of PI3K/AKT signaling pathway and epithelial-to-mesenchymal transition in non-small cell lung cancer,” European Review for Medical and Pharmacological Sciences, vol. 24, no. 11, pp. 6139–6149, 2020.